ArticlemBio2025
c-di-GMP regulates bacterial NAD biosynthesis via targeting the transcriptional repressor NadR.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research on the Potential Mechanism of Guanine Nucleotides Enhancing the Tolerance ofFoods (Basel, Switzerland) · 2026Article
- Previously Uncharacterised Aliphatic Amino Acid Positions Modulate the Apparent Catalytic Activity of the EAL Domain of ZMO_1055 and Other Cyclic Di-GMP-Specific EAL Phosphodiesterases.Microbial biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
As a near-ubiquitous bacterial second messenger, cyclic di-GMP (c-di-GMP) regulates a multitude of important biological processes. The regulatory effects of c-di-GMP on bacterial physiological processes are mediated through its interaction with various effector molecules, including mRNA riboswitches and proteins. Although c-di-GMP effector proteins have been widely reported, yet unknown c-di-GMP effectors in bacteria wait to be discovered, and the physiological roles of this second messenger still remain to be explored. In a c-di-GMP/transcription factor binding screen, we identified NadR, a repressor of nicotinamide adenine dinucleotide (NAD) synthesis and salvage, as a c-di-GMP-responsive transcription factor in IMPORTANCE: Cyclic di-GMP (c-di-GMP) functions as a highly versatile signaling molecule in bacteria, orchestrating diverse physiological processes critical for survival and adaptation. While nicotinamide adenine dinucleotide (NAD) plays pivotal roles in numerous cellular processes and functions, bacteria have been shown to modulate its biosynthetic and recycling pathways through a variety of regulatory mechanisms. However, a connection between c-di-GMP signaling and NAD metabolism in bacteria has never been revealed before. Here, we identify NadR, a transcriptional repressor of NAD synthesis and salvage, as a c-di-GMP effector, and show that c-di-GMP upregulates NAD biosynthesis by activating NadR-repressed genes, thus enhancing the defense of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.